Keyphrases
Tuberous Sclerosis Complex
100%
Mouse Model
100%
Seizure
100%
ERK Pathway
100%
MEK-ERK
37%
Mammalian Target of Rapamycin (mTOR)
25%
ERK Activity
25%
Clinically Significant
12%
Monogenic
12%
Signaling Pathway
12%
Hyperactivity
12%
Neuropathology
12%
Intractable Epilepsy
12%
Overgrowth
12%
Potential Alternatives
12%
MEK Inhibitor (MEKi)
12%
MTOR Inhibitor
12%
Everolimus
12%
Mouse Modeling
12%
Novel Therapeutic Targets
12%
Brain Malformation
12%
Complex Patients
12%
Seizure Activity
12%
PD0325901
12%
Developmental Brain
12%
Neuronal Dendrites
12%
ERK Inhibition
12%
Seizure Suppression
12%
Pharmacology, Toxicology and Pharmaceutical Science
Mouse Model
100%
Tuberous Sclerosis
100%
Mitogen Activated Protein Kinase Kinase Inhibitor
12%
Mammalian Target of Rapamycin Inhibitor
12%
Brain Malformation
12%
Intractable Epilepsy
12%
Everolimus
12%
N (2,3 Dihydroxypropoxy) 3,4 Difluoro 2 (2 Fluoro 4 Iodoanilino)benzamide
12%
Monogenic Disorder
12%